ArticleKorean journal of radiology2021
Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification.
Article in Korean journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Evaluation of locoregional invasiveness of early lung adenocarcinoma manifesting as ground-glass nodules via [European journal of nuclear medicine and molecular imaging · 2025Trial
- Diagnostic utility of tumor volume doubling time in ciliated muconodular papillary tumor/bronchiolar adenoma mimicking invasive mucinous adenocarcinoma: A case report.Radiology case reports · 2026Article
- Deep learning-based computed tomography quantification integrated with circulating tumor cells for prognostic evaluation in stage I lung adenocarcinoma.Quantitative imaging in medicine and surgery · 2026Article
- Development and validation of a dual-attention deep learning prediction model for noninvasive differentiation of pulmonary invasive mucinous adenocarcinoma from inflammatory pulmonary nodules.Translational lung cancer research · 2026Article
- A narrative review on CT-based evaluation and prediction of lung nodule growth: current status and future directions.Translational lung cancer research · 2026Review
- Predicting pulmonary nodule growth from a single time point: a fusion model of radiomics and deep learning to optimize follow-up strategies.Journal of thoracic disease · 2026Article
- Advanced characterization and grading of invasive lung adenocarcinoma: integrative analysis with spectral CT andQuantitative imaging in medicine and surgery · 2026Article
- Clinical characteristics, prognosis, and nomograms for lung invasive mucinous adenocarcinoma with distant metastasis: a population-based study.Translational cancer research · 2026Article
- Unique Clinical Features of Imaging-Stage I Peripheral Lung Squamous Cell Carcinoma: A Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Assessing Invasiveness of Ground-Glass Nodules Using Ternary-Class CT Radiomics Models: A Multi-Center Study with SHAP Explanations.Cancer management and research · 2026Article
- CircCDK6 Regulates Stemness Maintenance and Cisplatin Resistance in Lung Adenocarcinoma via the Wnt/β-Catenin Signaling Pathway.Cancer management and research · 2026Article
- Improvement of machine learning models for predicting high-grade subtypes of lung adenocarcinoma based on delta radiomics: A multicenter cohort study.European journal of radiology open · 2025Article
- Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies.World journal of surgical oncology · 2025Review
- A clinical spectrum of resectable lung adenocarcinoma with micropapillary component (MPC) concurrently presenting as mixed ground-glass opacity nodules.Cancer biomarkers : section A of Disease markers · 2025Article
- Nomogram model for the diagnosis of solitary nodular pulmonary mucinous adenocarcinoma.Scientific reports · 2024Article
- Diagnostic Potential of Supplemental Static and DynamicJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Prediction of the stage shift growth of early-stage lung adenocarcinomas by volume-doubling time.Quantitative imaging in medicine and surgery · 2024Article
- A solitary pulmonary nodule in a former glass blower mimicking a primary lung adenocarcinoma.International journal of surgery case reports · 2024Article
- Predicting pathological grade of stage I pulmonary adenocarcinoma: a CT radiomics approach.Frontiers in oncology · 2024Article
- Case report: Pulmonary sarcomatoid carcinoma demonstrating rapid growth on follow-up CT.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the tumor doubling time of invasive lung adenocarcinoma according to the International Association of the Study for Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) histologic classification. MATERIALS AND
methodsAmong the 2905 patients with surgically resected lung adenocarcinoma, we retrospectively included 172 patients (mean age, 65.6 ± 9.0 years) who had paired thin-section non-contrast chest computed tomography (CT) scans at least 84 days apart with the same CT parameters, along with 10 patients with squamous cell carcinoma (mean age, 70.9 ± 7.4 years) for comparison. Three-dimensional semiautomatic segmentation of nodules was performed to calculate the volume doubling time (VDT), mass doubling time (MDT), and specific growth rate (SGR) of volume and mass. Multivariate linear regression, one-way analysis of variance, and receiver operating characteristic curve analyses were performed.
resultsThe median VDT and MDT of lung cancers were as follows: acinar, 603.2 and 639.5 days; lepidic, 1140.6 and 970.1 days; solid/micropapillary, 232.7 and 221.8 days; papillary, 599.0 and 624.3 days; invasive mucinous, 440.7 and 438.2 days; and squamous cell carcinoma, 149.1 and 146.1 days, respectively. The adjusted SGR of volume and mass of the solid-/micropapillary-predominant subtypes were significantly shorter than those of the acinar-, lepidic-, and papillary-predominant subtypes. The histologic subtype was independently associated with tumor doubling time. A VDT of 465.2 days and an MDT of 437.5 days yielded areas under the curve of 0.791 and 0.795, respectively, for distinguishing solid-/micropapillary-predominant subtypes from other subtypes of lung adenocarcinoma.
conclusionThe tumor doubling time of invasive lung adenocarcinoma differed according to the IASCL/ATS/ERS histologic classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.